Search research articles
Contact Us
Filters
Showing results (261-270 of 288) with videos related to
Page
of 29
Sort By:
The Lancet. HIV
|
March 6, 2017
Switching from tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study
Chloe Orkin, Edwin DeJesus, Moti Ramgopal, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
September 9, 2025
Changing clinical and laboratory characteristics of Progressive Multifocal Leukoencephalopathy: a retrospective national cohort study
Ilaria Mainardi, Simonetta Gerevini, Andrea Tarantino, et al.
Antiviral Therapy
|
September 17, 2013
Durability of lopinavir/ritonavir monotherapy in individuals with viral load ≤50 copies/ml in an observational setting
Antonella d'Arminio Monforte, Nicola Gianotti, Alessandro Cozzi-Lepri, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)
|
April 21, 2010
Raltegravir versus Efavirenz regimens in treatment-naive HIV-1-infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses
Jeffrey L Lennox, Edwin Dejesus, Daniel S Berger, et al.
The Lancet. Infectious Diseases
|
May 14, 2013
Efficacy and safety of raltegravir for treatment of HIV for 5 years in the BENCHMRK studies: final results of two randomised, placebo-controlled trials
Joseph J Eron, David A Cooper, Roy T Steigbigel, et al.
The New England Journal of Medicine
|
October 4, 2008
Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection
Gerd Fätkenheuer, Mark Nelson, Adriano Lazzarin, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
June 30, 2007
Predictors of virological outcome and safety in primary HIV type 1-infected patients initiating quadruple antiretroviral therapy: QUEST GW PROB3005
Bruno Hoen, David A Cooper, Fiona C Lampe, et al.
Hepatology International
|
February 18, 2017
Efficacy and safety of daclatasvir plus pegylated-interferon alfa 2a and ribavirin in previously untreated HCV subjects coinfected with HIV and HCV genotype-1: a Phase III, open-label study
Mark S Sulkowski, Walford J Fessel, Adriano Lazzarin, et al.
Open Forum Infectious Diseases
|
September 27, 2017
Safety and Efficacy of Ombitasvir, Paritaprevir With Ritonavir ± Dasabuvir With or Without Ribavirin in Patients With Human Immunodeficiency Virus-1 and Hepatitis C Virus Genotype 1 or Genotype 4 Coinfection: TURQUOISE-I Part 2
Jürgen K Rockstroh, Chloe Orkin, Rolando M Viani, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
January 21, 2010
Long-term efficacy and safety of Raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 Phase III trials
Roy T Steigbigel, David A Cooper, Hedy Teppler, et al.
Page
of 29
Search research articles
Search
Showing results (261-270 of 288) with videos related to
Sort By:
Page
of 29
The Lancet. HIV
|
March 6, 2017
Switching from tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study
Chloe Orkin, Edwin DeJesus, Moti Ramgopal, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
September 9, 2025
Changing clinical and laboratory characteristics of Progressive Multifocal Leukoencephalopathy: a retrospective national cohort study
Ilaria Mainardi, Simonetta Gerevini, Andrea Tarantino, et al.
Antiviral Therapy
|
September 17, 2013
Durability of lopinavir/ritonavir monotherapy in individuals with viral load ≤50 copies/ml in an observational setting
Antonella d'Arminio Monforte, Nicola Gianotti, Alessandro Cozzi-Lepri, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)
|
April 21, 2010
Raltegravir versus Efavirenz regimens in treatment-naive HIV-1-infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses
Jeffrey L Lennox, Edwin Dejesus, Daniel S Berger, et al.
The Lancet. Infectious Diseases
|
May 14, 2013
Efficacy and safety of raltegravir for treatment of HIV for 5 years in the BENCHMRK studies: final results of two randomised, placebo-controlled trials
Joseph J Eron, David A Cooper, Roy T Steigbigel, et al.
The New England Journal of Medicine
|
October 4, 2008
Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection
Gerd Fätkenheuer, Mark Nelson, Adriano Lazzarin, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
June 30, 2007
Predictors of virological outcome and safety in primary HIV type 1-infected patients initiating quadruple antiretroviral therapy: QUEST GW PROB3005
Bruno Hoen, David A Cooper, Fiona C Lampe, et al.
Hepatology International
|
February 18, 2017
Efficacy and safety of daclatasvir plus pegylated-interferon alfa 2a and ribavirin in previously untreated HCV subjects coinfected with HIV and HCV genotype-1: a Phase III, open-label study
Mark S Sulkowski, Walford J Fessel, Adriano Lazzarin, et al.
Open Forum Infectious Diseases
|
September 27, 2017
Safety and Efficacy of Ombitasvir, Paritaprevir With Ritonavir ± Dasabuvir With or Without Ribavirin in Patients With Human Immunodeficiency Virus-1 and Hepatitis C Virus Genotype 1 or Genotype 4 Coinfection: TURQUOISE-I Part 2
Jürgen K Rockstroh, Chloe Orkin, Rolando M Viani, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
January 21, 2010
Long-term efficacy and safety of Raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 Phase III trials
Roy T Steigbigel, David A Cooper, Hedy Teppler, et al.
Page
of 29